REVERCE: Randomized phase II study of regorafenib followed by cetuximab versus the reverse sequence for metastatic colorectal cancer patients previously treated with fluoropyrimidine, oxaliplatin, and irinotecan: Quality of life analysis
2018 ◽
Vol 36
(15_suppl)
◽
pp. 3510-3510
◽
2013 ◽
Vol 33
(4)
◽
pp. 216-221
◽
Keyword(s):
Are gender-associated differences in quality of life in colorectal cancer patients disease-specific?
2009 ◽
Vol 18
(5)
◽
pp. 547-555
◽
Keyword(s):
2015 ◽
Vol 68
(3)
◽
pp. 266-278
◽
1992 ◽
Vol 15
(2)
◽
pp. 115-118
◽